StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) in a research note released on Sunday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Tenax Therapeutics Stock Up 0.3 %
Shares of TENX stock opened at $3.18 on Friday. The firm’s 50-day moving average is $3.43 and its two-hundred day moving average is $6.92. Tenax Therapeutics has a 12 month low of $2.77 and a 12 month high of $61.20.
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.72). As a group, equities analysts predict that Tenax Therapeutics will post -7.96 EPS for the current fiscal year.
About Tenax Therapeutics
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Read More
- Five stocks we like better than Tenax Therapeutics
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- Russell 2000 Index, How Investors Use it For Profitable Trading
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.